High cumulative incidence of cancer in patients with cardio-renal-anaemia syndrome

European Journal of Heart Failure

Volumn 12, Issue 8, 2010, Pages 855-860

  Schroten, Nicolas F ^a,b   Van Der Putten, Karien ^b   Rutten, Frans H ^a   Diepenbroek, Adry ^b   Mosterd, Arend ^a,b   Gaillard, Carlo A J M ^b,c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b MEANDER MEDICAL CENTER   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Anaemia; Cancer; Cardio renal syndrome; Heart failure; Kidney disease; Renal failure

Indexed keywords

CREATININE; HEMOGLOBIN;

ADULT; AGED; ANEMIA; ARTICLE; CANCER INCIDENCE; CANCER RISK; CARDIO RENAL ANEMIA SYNDROME; CASE CONTROL STUDY; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; HEART FAILURE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NEOPLASM; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

AGED; ANEMIA; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; ERYTHROPOIETIN; FEMALE; HEART FAILURE; HUMANS; INCIDENCE; KIDNEY FAILURE, CHRONIC; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASMS; NETHERLANDS; ODDS RATIO; RECEPTORS, ERYTHROPOIETIN; RETROSPECTIVE STUDIES; RISK FACTORS; SYNDROME;

EID: 77955434579     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfq078     Document Type: Article

References (30)

1. Bongartz LG, Cramer MJ, Doevendans PA, Joles JA, Braam B. The severe cardiorenal syndrome: 'Guyton revisited'. Eur Heart J 2005;26:11-17.
2. Jie KE, Verhaar MC, Cramer MJ, van der Putten K, Gaillard CA, Doevendans PA, Koomans HA, Joles JA, Braam B. Erythropoietin and the cardiorenal syndrome: cellular mechanisms on the cardiorenal connectors. Am J Physiol Renal Physiol 2006;291:F932-F944.
3. Hardee ME, Arcasoy MO, Blackwell KL, Kirkpatrick JP, Dewhirst MW. Erythropoietin biology in cancer. Clin Cancer Res 2006;12:332-339.
4. Lipsic E, Westenbrink BD, van der Meer P, van der Harst P, Voors AA, van Veldhuisen DJ, Schoemaker RG, van Gilst WH. Low-dose erythropoietin improves cardiac function in experimental heart failure without increasing haematocrit. Eur J Heart Fail 2008;10:22-29.
5. Fehr T, Ammann P, Garzoni D, Korte W, Fierz W, Rickli H, Wuthrich RP. Interpretation of erythropoietin levels in patients with various degrees of renal insufficiency and anemia. Kidney Int 2004;66:1206-1211.
6. Radtke HW, Claussner A, Erbes PM, Scheuermann EH, Schoeppe W, Koch KM. Serum erythropoietin concentration in chronic renal failure: relationship to degree of anemia and excretory renal function. Blood 1979;54:877-884.
7. Westenbrink BD, Visser FW, Voors AA, Smilde TD, Lipsic E, Navis G, Hillege HL, van Gilst WH, van Veldhuisen DJ. Anaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production, but to fluid retention as well. Eur Heart J 2007;28:166-171.
8. Nangaku M, Inagi R, Miyata T, Fujita T. Hypoxia and hypoxia-inducible factor in renal disease. Nephron Exp Nephrol 2008;110:e1-e7.
9. Rankin EB, Biju MP, Liu Q, Unger TL, Rha J, Johnson RS, Simon MC, Keith B, Haase VH. Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo. J Clin Invest 2007;117:1068-1077.
10. Jelkmann W. Molecular biology of erythropoietin. Intern Med 2004;43:649-659.
11. Miller JA. Losartan may modulate erythropoietin production. J Renin Angiotensin Aldosterone Syst 2001;2:255-260.
12. Wang AY, Yu AW, Lam CW, Yu LM, Li PK, Goh J, Lui SF. Effects of losartan or enalapril on hemoglobin, circulating erythropoietin, and insulin-like growth factor-1 in patients with and without posttransplant erythrocytosis. Am J Kidney Dis 2002;39:600-608.
13. Freudenthaler SM, Schreeb K, Korner T, GleiterCH. Angiotensin II increases erythropoietin production in healthy human volunteers. Eur J Clin Invest 1999;29:816-823.
14. van der Putten K, Braam B, Jie KE, Gaillard CA. Mechanisms of Disease: erythropoietin resistance in patients with both heart and kidney failure. Nat Clin Pract Nephrol 2008;4:48-57.
15. Spano JP, Milano G, Rixe C, Fagard R. JAK/STATsignalling pathway in colorectal cancer: a newbiological target with therapeutic implications. Eur J Cancer 2006;42:2668-2670.
16. Mohyeldin A, Lu H, Dalgard C, Lai SY, Cohen N, Acs G, Verma A. Erythropoietin signaling promotes invasiveness of human head and neck squamous cell carcinoma. Neoplasia 2005;7:537-543.
17. Acs G, Zhang PJ, McGrath CM, Acs P, McBroom J, Mohyeldin A, Liu S, Lu H, Verma A. Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression. Am J Pathol 2003;162:1789-1806.
18. Mannello F, Tonti GAM. Erythropoietin and its receptor in breast cancer: putting together the pieces of the puzzle. Oncologist 2008;13:761-768.
19. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-867.
20. Wong G, Hayen A, Chapman JR, Webster AC, Wang JJ, Mitchell P, Craig JC. Association of CKD and cancer risk in older people. J Am Soc Nephrol 2009;20: 1341-1350.
21. Holley JL. Screening, diagnosis, and treatment of cancer in long-term dialysis patients. Clin J Am Soc Nephrol 2007;2:604-610.
22. Mandayam S, Shahinian VB. Are chronic dialysis patients at increased risk for cancer? J Nephrol 2008;21:166-174.
23. Iseki K, Osawa A, Fukiyama K. Evidence for increased cancer deaths in chronic dialysis patients. Am J Kidney Dis 1993;22:308-313. (Pubitemid 23236639)
24. Stewart JH, Buccianti G, Agodoa L, Gellert R, McCredie MR, Lowenfels AB, Disney AP, Wolfe RA, Boyle P, Maisonneuve P. Cancers of the kidney and urinary tract in patients on dialysis for end-stage renal disease: analysis of data from the United States, Europe, and Australia and New Zealand. J Am Soc Nephrol 2003;14:197-207.
25. Port FK, Ragheb NE, Schwartz AG, Hawthorne VM. Neoplasms in dialysis patients: a population-based study. Am J Kidney Dis 1989;14:119-123.
26. Cengiz K. Increased incidence of neoplasia in chronic renal failure (20-year experience). Int Urol Nephrol 2002;33:121-126.
27. Smilde TD, van Veldhuisen DJ, Navis G, Voors AA, Hillege HL. Drawbacks and prognostic value of formulas estimating renal function in patients with chronic heart failure and systolic dysfunction. Circulation 2006;114:1572-1580.
28. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008;10:933-989.
29. Newcombe RG. Improved confidence intervals for the difference between binomial proportions based on paired data. Stat Med 1998;17:2635-2650.
30. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R. TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361:2019-2032.